

Bypass of Tumor Drug Resistance by Antivascular Therapy¹

Dina Preise*, Ohad Mazor*, Natalia Koudinova*, Mordechai Liscovitch*, Avigdor Scherz^{†,2} and Yoram Salomon^{*,2}

Departments of *Biological Regulation and [†]Plant Sciences, The Weizmann Institute of Science, Rehovot, Israel

Abstract

Multidrug resistance (MDR) presents a major obstacle for the successful chemotherapy of cancer. Its emergence during chemotherapy is attributed to a selective process, which gives a growth advantage to MDR cells within the genetically unstable neoplastic cell population. The pleiotropic nature of clinical MDR poses a great difficulty for the development of treatment strategies that aim at blocking MDR at the tumor cell level. Targeting treatment to the nonmalignant vascular network—the lifeline of the tumor—is a promising alternative for the treatment of drug-resistant tumors. The present study demonstrates that MDR in cancer can be successfully circumvented by photodynamic therapy (PDT) using an antivascular treatment protocol. We show that, although P-glycoprotein-expressing human HT29/MDR colon carcinoma cells in culture are resistant to PDT with Pd-bacteriopheophorbide (TOOKAD), the same treatment induces tumor necrosis with equal efficacy (88% vs 82%) in HT29/MDR-derived xenografts and their wild type counterparts, respectively. These results are ascribed to the rapid antivascular effects of the treatment, supporting the hypothesis that MDR tumors can be successfully eradicated by indirect approaches that bypass their inherent drug resistance. We suggest that with progress in ongoing clinical trials, TOOKAD–PDT may offer a novel option for local treatment of MDR tumors.

Neoplasia (2003) 5, 475–480

Keywords: multidrug resistance, P-glycoprotein, photodynamic therapy, TOOKAD, antivascular therapy.

Introduction

Resistance to chemotherapy with structurally and functionally unrelated drugs is attributed to a selection process that originates from the genetic instability of cancer cell populations—the primary target of treatment—along with the selection pressure applied by chemotherapeutic agents [1]. Clinical studies have shown that multidrug resistance (MDR) is often associated with poor patient prognosis, underscoring the urgency for overcoming this problem [2]. The ultimate objective of MDR research is to improve treatment outcome by developing strategies that prevent the emergence or circumvent existing MDR [3]. However, the classic approaches that inhibit drug efflux mediated by various adenosine triphosphate (ATP)–dependent MDR

transporters, such as P-glycoprotein (Pgp) and others [4], were so far unsuccessful. The main complications in these strategies are: 1) pharmacokinetic interactions between the MDR inhibitor and the anticancer drug; 2) inhibition of the same transport systems in healthy tissues, causing multiple adverse effects [3]; and 3) failure to overcome MDR by focusing on a specific pathway due to the multifactorial nature of clinical resistance [2]. This situation strengthens the necessity of developing new strategies that do not target the malignant cells directly, but rather aim at destroying nonmalignant tumor components that are crucial for tumor survival and development. A key system for such an indirect targeting is tumor vasculature, which is critical for maintaining tumor growth and development. In addition, endothelial cells are genetically stable and unlikely to develop MDR [5]. Antiangiogenic [1,6] and antivascular [5] cancer therapies are examples for strategies that target the blood vessels, and thus may provide a bypass for MDR. Several antiangiogenic agents, mostly inhibitors of vascular endothelial growth factor (VEGF), are now under extensive investigation as anticancer agents [7]. There is also a clinical report about the treatment of refractory multiple myeloma patients with thalidomide, in which response to treatment is attributed to an antiangiogenic mechanism [8]. The exact mechanism of anticancer activity of thalidomide is still unclear and may be contributed, for example, by immunomodulation. In contrast to antiangiogenic therapy that prevents neovascularization, antivascular chemotherapy [9] or photodynamic therapy (PDT) performed with high sensitizer concentration in the circulation [10,11] targets existing tumor blood vessels, leading to their occlusion with subsequent hypoxia, necrosis, and consequent tumor destruction [5].

PDT is a binary treatment modality consisting of systemic administration of a nontoxic substance—the photosensitizer (drug)—and local illumination of the target tumor at a wavelength that matches the sensitizer absorption maximum. Upon photosensitization, the molecule is excited and, by energy transfer to oxygen or by free radical-forming mechanisms, generates cytotoxic singlet oxygen and/or other highly reactive oxygen species (ROS) within the tumor. Such ROS react

Address all correspondence to: Dr. Yoram Salomon, Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel. E-mail: yoram.salomon@weizmann.ac.il

¹This work was supported by STEBA-BIOTECH (France).

²Equal contribution.

Received 1 May 2003; Revised 26 June 2003; Accepted 2 July 2003.

Copyright © 2003 Neoplasia Press, Inc. All rights reserved 1522-8002/03/\$25.00

rapidly with vital cellular components (such as membranes, cytoskeleton, and DNA), causing cellular damage and death [12]. One of the advantages of PDT is the ability to selectively deliver local treatment, thus avoiding injury of healthy tissues, which is the greatest problem of conventional chemotherapies and radiotherapies.

We have synthesized a novel family of photosensitizers, derived from the photosynthetic pigment bacteriochlorophyll [13,14], notably Pd-bacteriopheophorbide (TOOKAD) [14], presently found in clinical trials for prostate cancer therapy in collaboration with Steba Biotech (Toussus Le-Noble, France). In comparison with most clinically used photosensitizers, the bacteriochlorophyll-based photosensitizers, including TOOKAD, exhibit advantageous photochemical and pharmacological characteristics, namely: 1) high extinction coefficient in the near-infrared (IR) ($\epsilon_0 \sim 10^5$ at 763 nm), enabling treatment of bulky tumors to a depth of 2 cm [10,13,15]; and 2) rapid clearance from the circulation ($T_{0.5} = 0.6$ minute) and skin (no phototoxicity at times >1 hour after treatment; Koudinova et al., 2002, unpublished), which minimizes skin phototoxicity. In addition, the PDT treatment protocol where the sensitizer and the light are simultaneously administered was shown in our laboratory to be an antivascular modality that selectively induces tumor blood vessel occlusion and stasis within minutes of illumination [16,17]. This protocol leads to the development of local ischemia, culminating with necrosis (24–48 hours) and ultimate tumor eradication (weeks) [10,11,15,18].

In the present study, we demonstrate that although human HT29/MDR colon carcinoma cells are resistant to TOOKAD–PDT in culture, the same treatment has equal efficacy when applied to the respective MDR xenografts and their wild type (WT) counterparts. This proof of concept suggests that by targeting the tumor vasculature, cancer therapies such as TOOKAD–PDT can overcome MDR and provide effective treatment for these malignancies.

Materials and Methods

Cultured Cells

Human isogenic HT29/WT and MDR cells were obtained from Prof. I. Z. Cabantchik (Hebrew University of Jerusalem) and cultured at 37°C in a humidified atmosphere containing 8% CO₂. The MDR cells were maintained in the presence of 300 ng/ml colchicine [19], which was washed from the cultured MDR cells 24 hours before the experiments.

Animals

Male CD1 nude mice (28–32 g) were housed in The Weizmann Institute animal facility and all experimental procedures were conducted according to institute guidelines (1996).

Tumor Model

Human WT and MDR HT29 cell monolayers were scraped in saline, washed, resuspended in saline, and injected subcutaneously ($4-6 \times 10^6$ cells/0.07 ml per mouse) into the

back of the mice. Tumors reached a treatment size (6–8 mm) within 2 (WT) and 4–5 (MDR) weeks. Mice bearing tumors (≥ 15 mm) were euthanized by anesthetic overdose.

Light Sources

Light source 1 A-home built 250-W halogen lamp focused through a 4-cm water filter fitted with a cutoff filter ($\lambda < 650$ nm) was used for *in vitro* studies.

Light source 2: A 763-nm diode laser (1 W; CERAMOPTEC, Bonn, Germany) was used for *in vivo* studies.

Photosensitizer

In vitro studies TOOKAD, synthesized in our laboratory [14], was dissolved in ethanol immediately before use and further diluted to the final concentration in culture medium containing 1% ethanol.

In vivo studies TOOKAD (2.5 mg/ml) was administered in 5% Cremophor EI–based formulation (NEGMA-LERADS, Toussus-Le-Noble, France).

PDT Protocol

In vitro studies Cells ($4-6 \times 10^4$ per well) were plated in 96-well plates and cultured for 24 hours. The cells were then preincubated in the dark (4 hours) with the indicated TOOKAD concentrations, washed with fresh medium, and illuminated from below at a dose of 12 J/cm². After illumination, the cells were placed in the culture incubator and cell survival was determined after 24 hours using the neutral red viability assay.

In vivo studies Mice, anesthetized by intraperitoneal injection of 40 μ l of a mixture of ketamine (Rhone Merieux, Lyon, France) and xylazine 2% (Vitamed, Hedera, Israel) (85:15 vol:vol), were injected intravenously with 10 mg/kg TOOKAD, and the tumor was immediately illuminated (field $\Phi = 14$ mm) at a dose of 90 J/cm². Tumor response (using local necrosis on day 8 post-PDT as an endpoint) was photographically recorded and tumor volume was assessed [20].

Controls *Dark control*—cells or mice treated with TOOKAD but not illuminated. *Light control*—cells illuminated without incubation with TOOKAD, or mice intravenously injected with vehicle and illuminated. *Untreated control*—no light or drug (served as 100% cell survival for *in vitro* studies).

Histology

Tumors were excised from sacrificed animals, fixed in 4% formaldehyde in phosphate-buffered saline (PBS) at room temperature (RT; 48 hours), and paraffin-embedded. Sections were prepared and stained with hematoxylin/eosin (HNE) using standard protocols.

Immunohistochemistry

Cultured cells Cells were grown on coverslips (48 hours), washed with PBS, and briefly fixed (5 minutes, 2% paraformaldehyde at 4°C). Samples were then blocked (1 hour, 2% BSA, and 20% horse serum in PBS at RT). Cells were stained for Pgp by overnight incubation with 20 μ g/ml monoclonal anti-human Pgp antibodies (4E3; Dako,




Figure 1. Resistance of human HT29/MDR cells to TOOKAD-PDT. (A) Cells were preincubated in the dark with TOOKAD, washed, and illuminated. Closed circles, WT/dark; open circles, WT/PDT; closed squares, MDR/dark; open squares, MDR/PDT. The graphs represent the mean \pm SE of four independent experiments performed in triplicates. Cell survival is presented as a percentage of untreated control. *No significant difference between values (MDR/dark and MDR/PDT) by Fisher's LSD test. (B and C) Immunostaining for Pgp of cultured HT29 MDR and WT cells, respectively. (B, inset) Immunoblot of the respective cell lysates with anti-Pgp antibodies. Bands representing α -tubulin (55 kDa) and Pgp (170 kDa) are shown. (D) TOOKAD-PDT of HT29/MDR cells in the absence (closed squares, dark/VP-; open squares, PDT/VP-) or presence (closed triangles, dark/VP+; open triangles, PDT/VP+) of 50 μ M VP. Cells were preincubated with VP for 30 minutes prior to the standard PDT protocol. The curves represent the mean \pm SE of three independent experiments performed in triplicates. Cell survival is presented as percent of untreated control.

Carpinteria, CA) at 4°C, followed by treatment with alkaline phosphatase (AP)-conjugated goat anti-mouse antibodies (Promega, Madison, WI) using fast red (Sigma, St. Louis, MO) as a color substrate.

Tumor sections Paraffin-embedded sections were deparaffinized with xylene and rehydrated by serial 5-minute incubations in 100%, 95%, and 70% ethanol and water. Endogenous peroxidases were inactivated by incubation in 3% H₂O₂ (Merck, Darmstadt, Germany), followed by blocking with 1% bovine serum albumin (BSA; Sigma) and 2% goat serum in PBS. Sections were incubated overnight (4°C) with 20 μ g/ml 4E3 Pgp, or with polyclonal anti-HNE antibodies (1:500; Calbiochem, San Diego, CA). Sections were then treated (1 hour at RT) with goat anti-mouse or goat anti-rabbit peroxidase-conjugated antibodies (Jackson, ME) using 3-amino-9-ethylcarbazole (AEC; Sigma) as color substrate.

Cells and sections were counterstained with 0.1% hematoxylin (Sigma). In the negative control, the primary antibodies were omitted. All intermediate washes were performed with PBS.

Light microscopy was performed using a microscope (Nikon Optiphot 2; Nikon, Tokyo, Japan) equipped with a digital camera (DVC Company, Austin, TX).

Preparation of Cell and Tissue Extracts

Cell lysates Cells were washed twice with cold PBS, scraped in RIPA [20 mM Tris-HCl, 137 mM NaCl, 10% glycerol, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholate, 1% Triton X-100, 2 mM EDTA, pH 8.0, 1 mM PMSF, 20 μ M leupeptin], sonicated for 10 seconds, centrifuged at 2×10^4g (15 minutes), and stored at -20°C until use. All steps were carried out on ice.

Tumor extracts Tumors were homogenized in RIPA. Homogenates were kept at 4°C (15 minutes) and centrifuged at 2×10^4g (10 minutes). The supernatant was collected and stored at -20°C until use.




Figure 2. Response of HT29 MDR and WT xenografts to TOOKAD-PDT. (A and B) Pgp immunostaining of MDR and WT xenografts. (B, inset) Immunoblot of respective tumor homogenates with anti-Pgp antibodies. Tubulin (55 kDa) and Pgp (170 kDa). (C and D) Tumors before and (E and F) 8 days after PDT. (G and H) Tumor growth curves starting from day of treatment (day 0). Diamonds, PDT; squares, light control; triangles, dark control; circles, untreated control. The number of mice per group was as follows: PDT (WT and MDR, $n = 17$ each), dark control (WT and MDR, $n = 6$ each), untreated (WT and MDR, $n = 4$ each), and light control (WT, $n = 8$ and MDR, $n = 5$). Bars represent mean \pm SE.

Table 1. The Response of Human HT29 WT and MDR Xenografts to PDT with TOOKAD.

Tumor Type	Number of Animals	Response (Necrosis on Day 8)	
		Complete	Partial
MDR	17	15 (88.2%)	1 (5.9%)
WT	17	14 (82.3%)	3 (17.6%)

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Immunoblot Analysis

Proteins (30–100 μ g protein per lane) were separated on 7.5% SDS-PAGE and blotted onto nitrocellulose membranes. Membranes were blocked with 10% milk and 1% goat serum in PBS. Pgp was identified using monoclonal anti-human Pgp antibodies (C219, 1:500; Alexis Biochem, Montreal, Canada) and peroxidase-conjugated or AP-conjugated goat anti-mouse IgG as secondary antibodies. Bands were visualized using ECL (Santa Cruz Biotechnology, Santa Cruz, CA) or incubation with fast red, respectively. α -Tubulin was detected with monoclonal anti- α -tubulin antibodies (Sigma).

Results

Cultured HT29/MDR Cells Are Resistant to TOOKAD–PDT

To demonstrate that the MDR phenotype renders HT29/MDR cells resistant to the direct effects of TOOKAD–PDT, we subjected cultured HT29/WT and MDR cells to TOOKAD–PDT *in vitro*. The WT cells responded to PDT in a TOOKAD concentration-dependent manner ($LD_{50}=0.3 \mu$ M), whereas no response was seen in the absence of light (dark control) (Figure 1A). In contrast, the MDR cells did not respond to PDT under the same experimental conditions ($LD_{50} \gg 5 \mu$ M) (the apparent decrease in cell survival in the MDR/PDT group was statistically insignificant ($P = .5$) by two-way analysis of variance (ANOVA).

The Pgp drug transporter is overexpressed in MDR cells [21]. To verify the presence of this marker in the HT29/MDR

variants, we subjected cells to immunostaining, and cell lysates to SDS-PAGE and immunoblotting using monoclonal anti-Pgp antibodies. As expected, Pgp staining was observed in the MDR (Figure 1B, *inset*) but not in WT cells (Figure 1C). It was thus presumed that if the resistance to TOOKAD–PDT is indeed Pgp-dependent, then preincubation of the MDR cells with verapamil (VP), a known inhibitor of Pgp [22], should sensitize them to the cytotoxic treatment. Indeed, we found that VP-pretreated HT29/MDR cells responded to TOOKAD–PDT (Figure 1D), specifically confirming the role of the Pgp efflux pump in the resistance of these cultured MDR cells to TOOKAD–PDT.

MDR HT29 Xenografts Are Sensitive to PDT with TOOKAD

It was hypothesized that although MDR cells are resistant to PDT *in vitro*, they should be susceptible to TOOKAD–PDT-mediated ablation of blood vessels *in vivo*. To test this idea, we subcutaneously implanted MDR or WT HT29 cells in mice and examined the effect of TOOKAD–PDT on the tumors *in vivo*. To verify the maintenance of the MDR phenotype in the xenografts, we examined Pgp expression by immunohistochemical analysis of tumor sections (Figure 2, A and B) and by immunoblotting of tumor homogenates using anti-Pgp antibodies (Figure 2B, *inset*). Only tumors derived from MDR cells showed positive staining for Pgp, whereas the WT tumors were negative, illustrating that the MDR phenotype was indeed maintained *in vivo*. Tumors that reached treatment size (Figure 2, C and D) were subjected to TOOKAD–PDT and the response to treatment was monitored by clinical and histopathological means. Both variants responded positively, as judged by necrosis on day 8 post-PDT (Figure 2, E and F). Further follow-up of tumor size showed growth inhibition of both WT and MDR tumors by PDT (Figure 2, G and H). In contrast, tumors in the control groups continued to grow (Figure 2, G and H). Furthermore, the observed efficacy of treatment on the MDR (88.2%) and WT (82.4%) tumors was almost identical (Table 1). When also considering animals with incomplete response (necrosis covering only part of the tumor), these results amount to (16/17, 94.1%) and (17/17,




Figure 3. Histological sections of MDR and WT xenografts. (A and B) HNE staining before and (C and D) 24 hours after PDT. (E and F) HNE immunostaining before and (G and H) 24 hours after PDT. Bars=50 μ m.

100%) respectively. Histopathological examination of both xenograft variants in comparison with untreated controls showed degenerative changes in the entire neoplastic population with clear-cut necrosis, including pyknosis and karyolysis in about 30–40% of the cells, 24 hours post-PDT [Figure 3, A and B (before PDT); Figure 3, C and D (24 hours after PDT)]. There were edema and mixed inflammatory infiltration in the surrounding tissues. Blood vessels were dilated and scattered necrotic debris was visible in the vicinity and within the walls of some dermal and subcutaneous vessels, away from the tumor together with extensive hemorrhage observed in both tumor types.

One of the common features of PDT-induced damage is local lipid peroxidation (LPO), which can be assessed immunohistochemically using 4-hydroxy-2-nonenal (HNE) as marker [10]. Analysis of PDT-induced LPO indicates that the degree of photodamage was similar in both tumor variants (Figure 3, E–H). Thus, both clinically and histopathologically, MDR and WT tumors responded similarly to PDT. The response of the MDR tumor variant to TOOKAD–PDT is therefore consistent with the antivascular activity of this treatment, which targets the nonmalignant host blood vessels—the only common denominator of the two tumor variants.

Discussion

In this study, we hypothesized that the inherent resistance of HT29/MDR cells to PDT with TOOKAD can be effectively circumvented when the respective xenografts are treated with antivascular treatment protocol. To prove this point in a controlled manner, we first demonstrated that in culture, HT29/MDR cells exhibit resistance to TOOKAD–PDT, whereas the respective WT cells are fully responsive (Figure 1A). We secondly grafted the same cells to CD1 nude mice and demonstrated that TOOKAD–PDT induces necrosis in xenografts derived from resistant HT29/MDR and isogenic WT counterparts with equal efficacy (Figure 2 and Table 1). Pgp expression was positively correlated with the MDR phenotype of the cultured MDR cells (Figure 1B) and with resistance to TOOKAD–PDT (Figure 1A), which was abolished by the inhibition of TOOKAD efflux by VP (Figure 1D). However, Pgp expression *in vivo* (Figure 2, E and B, inset) did not correlate with the tumor phenotype, where the MDR tumors responded well to TOOKAD–PDT (Figure 2, E and G; Figure 3, C and G). This finding is consistent with the notion that the PDT protocol used here does not target the tumor cells, but rather the host-derived vasculature, which is identical in both tumors. PDT with TOOKAD, like its predecessor bacteriochlorophyll serine [11], was shown to eradicate solid tumors by vascular destruction and blood stasis [16,17].

Furthermore, we previously showed that the antitumor activity of TOOKAD–PDT is secondary to the photodynamic induction of local hypoxia and necrosis [10] and is likely to be independent of the tumor type. In contrast to TOOKAD, most other photosensitizers used in experimental and clinical cancer therapies were designed to selectively accumulate

in and destroy the malignant cells and tumors upon illumination [23]. It is, therefore, not surprising that under culture conditions, PDT with sensitizers, such as Photofrin or copper benzochlorin iminium salt (CuBI), is generally [24,25], although not always [26], ineffective against MDR cells but effective against their parental WT variants, as is the case with TOOKAD. Although other sensitizers (Foscan, hypericin) were shown to exert vascular effects in animal models, the ability of this effect by itself to induce complete tumor eradication was not conclusive [27,28]. Verteporfin, however, is an agent designed as a specific antivascular modality and was introduced for treatment of age-related macular degeneration [29]. However, PDT with hydrophilic sensitizers such as monocationic porphyrin (MCP) and 5-aminolaevulinic acid (5-ALA) was found to be cytotoxic for both Pgp-expressing MDR and their parental WT variants in culture [30,31]. The sensitivity of MDR cells to these agents is thought to be because they are not recognized by Pgp. In agreement with these findings, the charged aluminum disulfonated phthalocyanine (AlS₂Pc) was found to be effective against MDR and WT murine tumors [32], yet no specific mechanism was indicated. It appears that the response to PDT with classic sensitizers may vary with tumor type, the nature of the sensitizer, and the specific MDR mechanism involved, limiting their use in the treatment of MDR tumors. In contrast, antivascular PDT with TOOKAD is predicted to be independent of tumor type and MDR mechanism. To the best of our knowledge, however, no controlled *in vivo* studies with clinically relevant photosensitizers reported successful treatment of MDR tumors. One can anticipate that the above-mentioned PDT agents bearing antivascular activity will behave similarly to TOOKAD in the treatment of MDR tumors depending on: 1) whether their sole antivascular action is sufficient to cause tumor eradication, as is the case for TOOKAD; and 2) if the respective MDR cells in culture are resistant to their photodynamic activity. The emergence of drug resistance in tumor therapy is a likely consequence of selection pressure promoted by chemotherapeutic drugs on the neoplastic component of the tumor, typically characterized by high mutation rates and genetic instability. In an attempt to develop strategies that circumvent this therapeutic risk, it was logical to approach the tumor indirectly by targeting its blood supply. Tumor-associated endothelial cells are nonmalignant and, as such, are less likely to develop resistance [1]. Their selective targeting by TOOKAD–PDT was, therefore, expected to succeed in cases where conventional cancer therapies failed.

Thus, results presented here support the hypothesis that by targeting the tumor vasculature, TOOKAD–PDT circumvents drug resistance of malignant tumor cells, permitting effective treatment of MDR tumors. Moreover, we presume that the brief, single, 10-minute PDT protocol itself is not likely to induce drug resistance.

In summary, this study suggests a new, promising strategy for effective treatment of drug-resistant tumors, based on targeting of the tumor blood vessels by TOOKAD–PDT. We hope that with progress in ongoing clinical trials, TOOKAD–PDT will also improve the treatment outcome for

patients with MDR tumors and enable cancer treatment where conventional chemotherapy fails.

Acknowledgements

Y.S. is the incumbent of the Tillie and Charles Lubin Professorial Chair in Biochemical Endocrinology. M.L. is the incumbent of the Harold L. Korda Professorial Chair in Biology. A.S. is the incumbent of the Robert and Yadele Sklare Professional Chair in Biochemistry. All the studies described here were performed by D.P. in partial fulfillment of her MSc thesis requirements at the Feinberg Graduate School of The Weizmann Institute of Science. We thank Prof. Edna Schechtman for help in the statistical analysis and Dr. Ori Brenner for assisting with the histopathologic analysis. We also thank Dana Ravid for helpful discussions.

References

- [1] Kerbel RS (1991). Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. *Bio-Essays* **13**, 31–36.
- [2] Lehnert M (1996). Clinical multidrug resistance in cancer: a multifactorial problem. *Eur J Cancer* **32A**, 912–20.
- [3] Liscovitch M, and Lavie Y (2002). Cancer multidrug resistance: a review of recent drug discovery research. *IDrugs* **5**, 349–55.
- [4] Krishna R, and Lawrence DM (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. *Eur J Pharm Sci* **11**, 265–83.
- [5] Chaplin DJ, and Dougherty GJ (1999). Tumor vasculature as a target for cancer therapy. *Br J Cancer* **80**, 57–64.
- [6] Folkman J (1995). Clinical application of research on angiogenesis. *N Engl J Med* **333**, 1757–763.
- [7] Ferrara N, and Alitalo, K (1999). Clinical applications of angiogenic growth factors and their inhibitors. *Nat Med* **5**, 1359–364.
- [8] Kneller A, Raanani P, Hardan I, Avigdor A, Levi I, Berkowicz M, and Ben-Bassat I (2000). Therapy with thalidomide in refractory multiple myeloma patients—the revival of an old drug. *Br J Haematol* **108**, 391–93.
- [9] Tozer GM, Kanthou C, Parkins CS, and Hill SA (2002). The biology of the combretastatins as tumour vascular targeting agents. *Int J Exp Pathol* **83**, 21–38.
- [10] Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, Eschhar Z, Scherz A, and Salomon Y (2003). Photodynamic therapy with Pd-bacteriopheophorbide (TOOKAD): successful *in vivo* treatment of human prostate small cell carcinoma xenografts. *Int J Cancer* **104**, 782–89.
- [11] Zilberstein J, Schreiber S, Bloemers MCWM, Bendel P, Neeman M, Schechtman E, Kohen F, Scherz A, and Salomon Y (2001). Antivascular treatment of solid melanoma tumors with bacteriochlorophyll-serine-based photodynamic therapy. *J Photochem Photobiol* **73**, 257–66.
- [12] Ackroyd R, Clive K, Brown N, and Reed M (2001). The history of photodetection and photodynamic therapy. *Photochem Photobiol* **74**, 656–69.
- [13] Scherz A, Feodor L, and Salomon Y (1997). Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmacological compositions comprising them. *US Patent 5,650,292*.
- [14] Scherz A, Salomon Y, Scheer H, and Brandis A (1999). Palladium-substituted bacteriochlorophyll derivatives and use thereof. *US Patent Application No. 09/857,772, US allowed (2003)*.
- [15] Chen Q, Huang Z, Luck D, Beckers J, Brun PH, Wilson BS, Scherz A, Salomon Y, and Hetzel FW (2002). Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancer. *Photochem Photobiol* **76**, 438–45.
- [16] Gross S, Scherz A, Neeman M, and Salomon Y (2002). Photodynamic therapy (PDT) of solid tumors with Pd-bacteriopheophorbide (WST09): functional imaging by blood oxygen level-dependant (BOLD) MRI. *Proceedings of the 10th Scientific Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM), Honolulu, HI (CD-ROM 2154)*.
- [17] Mazor O, Brandis A, Gross S, Hami R, Vakrat Y, Koudinova N, Gladysz E, Kostenitz G, Orenstien A, Salomon Y, and Scherz A (2002). Pd-bacteriopheophorbide (TOOKAD), a novel anti-vascular agent for photodynamic therapy of tumors: *in vitro* and *in vivo* studies. *The 3rd Congress of the Federation of Israel Societies for Experimental Biology, Book of Abstracts, Eilat, Israel*, 231.
- [18] Schreiber S, Gross S, Brandis A, Harmelin A, Rosenbach-Belkin V, Scherz A, and Salomon Y (2002). Local photodynamic therapy (PDT) of rat C6 glioma xenografts with Pd-bacteriopheophorbide leads to decreased metastases and increased animal cure compared with surgery. *Int J Cancer* **99**, 279–85.
- [19] Breuer W, Slotki IN, Ausiello DA, and Cabantchik IZ (1993). Induction of multidrug resistance downregulates the expression of CFTR in colon epithelial cells. *Am J Physiol* **265**, C1711–715.
- [20] Gleave ME (1992). Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. *Cancer Res* **52**, 1598–605.
- [21] Gottesman MM (1993). How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. *Cancer Res* **53**, 747–54.
- [22] Tsuruo T, Iida H, Tsukagoshi S, and Sakurai Y (1981). Overcoming of vincristine resistance in P388 leukemia *in vivo* and *in vitro* through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res* **41**, 1967–972.
- [23] Macdonald IJ, and Dougherty TJ (2001). Basic principles of photodynamic therapy. *J Porphyr Phthalocyanines* **5**, 105–29.
- [24] Singh G, Wilson BC, Sharkey SM, Browman GP, and Deschamps P (1991). Resistance to photodynamic therapy in radiation induced fibrosarcoma-1 and Chinese hamster ovary multidrug resistant cells *in vitro*. *Photochem Photobiol* **54**, 307–12.
- [25] Kessel D, Hampton J, Fingar V, and Morgan A (1998). Tumor versus vascular photodamage in rat tumor model. *J Photochem Photobiol B Biol* **45**, 25–27.
- [26] Dellinger M, Moreno G, Salet C, Tapiero H, and Lampidis TJ (1992). Cytotoxic and photodynamic effects of Photofrin on sensitive and multidrug resistant Freund leukaemia cells. *Int J Radiat Biol* **62**, 735–41.
- [27] Chen B, Roskams T, and Witte PAM (2002). Antivascular tumor eradication by hypericin-mediated photodynamic therapy. *Photochem Photobiol* **76**, 509–13.
- [28] Cramers P, Ruevekamp M, Oppelaar H, Dalesio O, Baas P, and Stewart FA (2003). Foscan uptake and tissue distribution in relation to photodynamic efficacy. *Br J Cancer* **88**, 283–90.
- [29] Fingar VH, Kik PK, Haydon PS, Cerrito PB, Tseng M, Abang E, and Wieman TJ (1999). Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). *Br J Cancer* **79**, 1702–708.
- [30] Kessel D, Woodburn K, Henderson BW, and Chang CK (1995). Sites of photodamage *in vivo* and *in vitro* by a cationic porphyrin. *Photochem Photobiol* **62**, 875–81.
- [31] Li W, Zhang WJ, Ohnishi K, Yamada I, Ohno R, and Hashimoto K (2001). 5-Aminolaevulinic acid-mediated photodynamic therapy in multidrug resistant leukemia cells. *J Photochem Photobiol B Biol* **60**, 79–86.
- [32] Canti G, Lattuada D, Morelli S, Nicolini A, Cubeddu R, Taroni P, and Valentini G (1995). Efficacy of photodynamic therapy against doxorubicin-resistant murine tumors. *Cancer Lett* **93**, 255–59.